Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

MELOXICAM CRS (50 MG)

MELOXICAM CRS (50 MG)

71125-38-7

DISCOVER
MEFENAMIC ACID IMPURITY A CRS(100 MG)

MEFENAMIC ACID IMPURITY A CRS(100 MG)

87-59-2

DISCOVER
FLUVASTATIN FOR SYSTEM SUITABILITY CRS (0.5 MG)

FLUVASTATIN FOR SYSTEM SUITABILITY CRS (0.5 MG)

93957-55-2

DISCOVER
METHYLDOPA FOR SYSTEM SUITABILITY CRS (0.024 MG)

METHYLDOPA FOR SYSTEM SUITABILITY CRS (0.024 MG)

41372-08-1

DISCOVER
ACETAZOLAMIDE FOR SYSTEM SUITABILITY CRS (0.007 MG)

ACETAZOLAMIDE FOR SYSTEM SUITABILITY CRS (0.007 MG)

59-66-5

DISCOVER
LAMOTRIGINE FOR SYSTEM SUITABILITY CRS (10 MG)

LAMOTRIGINE FOR SYSTEM SUITABILITY CRS (10 MG)

84057-84-1

DISCOVER
MEBROFENIN CRS (120 MG)

MEBROFENIN CRS (120 MG)

78266-06-5

DISCOVER
TETRA-O-ACETYL-MANNOSE TRIFLATE CRS (90 MG)

TETRA-O-ACETYL-MANNOSE TRIFLATE CRS (90 MG)

92051-23-5

DISCOVER
CYCLOPENTOLATE FOR SYSTEM SUITABILITY CRS (20 MG)

CYCLOPENTOLATE FOR SYSTEM SUITABILITY CRS (20 MG)

5870-29-1

DISCOVER
ATENOLOL FOR SYSTEM SUITABILITY CRS (5 MG)

ATENOLOL FOR SYSTEM SUITABILITY CRS (5 MG)

29122-68-7

DISCOVER
FLUVASTATIN SODIUM CRS (110 MG)

FLUVASTATIN SODIUM CRS (110 MG)

93957-55-2

DISCOVER
ARTICHOKE LEAF DRY EXTRACT HRS (60 MG)

ARTICHOKE LEAF DRY EXTRACT HRS (60 MG)

NA

DISCOVER